Tempus AI Share Price – Live Data, News & Predictions
Tempus AI, Inc. trades on the Nasdaq under the ticker TEM, offering investors exposure to the intersection of artificial intelligence and healthcare data analytics. Understanding the Tempus AI share price requires examining current trading levels, historical performance, recent news flow, and upcoming financial milestones that could influence the stock in the months ahead.
The company operates in a sector that has attracted significant capital flows throughout 2024 and 2025, with AI-driven healthcare solutions gaining prominence among institutional and retail investors alike. Trading volume and price volatility have reflected this heightened interest, making real-time price tracking and contextual analysis valuable for anyone monitoring TEM stock.
This article provides a comprehensive overview of the Tempus AI share price, drawing on verified market data, financial metrics, and available analyst signals to help readers understand where the stock stands and what factors may shape its trajectory going forward.
Tempus AI Share Price Prediction
Short-term price projections for TEM draw primarily from technical chart analysis and recent momentum patterns. TradingView analysts have identified key levels to watch, with the $70 support zone considered critical for maintaining bullish momentum. A breakout above the $76.80 to $77 resistance band could open paths toward the $80–95 range, with some technical projections pointing toward the $100 level depending on broader market conditions and continued volume expansion.
Current Trading Snapshot
Key Market Insights
- TEM has gained 98.24% over the past year, demonstrating strong momentum despite recent volatility
- Recent trading around $54.50 reflects intraday fluctuations, with prices ranging from $49.53 to $68.09 depending on timing
- The stock carries a beta of 2.74–3.04, indicating significantly higher volatility than the broader market
- Analyst price targets span from $60 to $110, with bullish signals suggesting potential for further upside
- Volume has consistently exceeded the average of 6.02 million shares, signaling sustained investor interest
- No dividend is currently reported, consistent with a growth-focused capital allocation strategy
| Metric | Value | Notes |
|---|---|---|
| Ticker | TEM | Nasdaq-listed |
| Market Cap | $9.76B–$15.91B | Varies by source and timing |
| P/E Ratio (TTM) | -38.68 to -40.09 | Negative due to ongoing losses |
| EPS (TTM) | -$1.18 | Basic earnings per share |
| Revenue (FY) | $693.40M | Fiscal year revenue |
| Net Income (FY) | -$705.81M | Net loss for fiscal year |
| 52-Week Range | $22.89–$104.32 | All-time low recorded at $22.89 |
| Beta | 2.74–3.04 | High volatility relative to market |
Tempus AI Share Price History
The Tempus AI share price has demonstrated considerable range since its current structure emerged. The stock reached its 52-week low of $22.89 on June 25, 2024, before embarking on an explosive rally that ultimately pushed prices to $104.32 on October 9, 2025. This represents a gain exceeding 350% from the yearly trough to peak.
Recent Price Movements
In recent trading sessions, TEM has experienced notable swings characteristic of high-beta growth stocks. A snapshot showed the stock trading at $54.50 with an intraday high of $58.07 and low of $52.91, while opening at $57.97. Volume of 8.76 million shares substantially exceeded the typical average of 6.02 million, indicating heightened market activity.
The weekly performance has shown mixed signals, with one period registering a 4.32% decline over seven days while the monthly view reflected a 10.98% gain. This choppiness underscores the importance of monitoring key support and resistance levels rather than reacting to short-term fluctuations.
Technical Chart Analysis
Technical analysts monitoring TradingView charts have identified the $70 level as a pivotal support zone for TEM. The stock experienced a significant rally following completion of the $74.65 structure, which catalyzed the move toward higher price levels. Current consolidation around the mid-$50s reflects the market digesting recent gains and positioning ahead of upcoming catalysts.
Support sits at $76.60 with resistance at $77.30. Traders watching for continuation should monitor whether price can establish and hold above the $70 support zone consistently.
Latest Tempus AI Share Price News
Recent developments have shaped sentiment around TEM in the near term. Most notably, Tempus AI announced securing $300 million in funding specifically designated for the Ambry Genetics acquisition, a strategic move reported approximately one day prior to the latest data. This acquisition aligns with Tempus AI’s broader mission of expanding its genomic testing and data capabilities within the healthcare AI ecosystem.
Financial Performance Highlights
The most recent quarterly report delivered encouraging headlines for investors focused on top-line growth. Revenue of $314.63 million exceeded analyst estimates of $297.74 million, while the EPS loss of $0.22 narrowly beat expectations of a $0.23 loss per share—a positive variance of 4.30%. Perhaps most significantly, net income of -$42.84 million represented a 37.03% improvement quarter-over-quarter, suggesting the company is making meaningful progress toward narrowing its losses.
Looking ahead, the next earnings release is scheduled for November 4, 2025, covering Q3 2025 results. Analysts are projecting EPS of -$0.19 and revenue of $328.86 million, continuing the trajectory of revenue growth that has characterized recent periods.
Tempus AI is scheduled to report Q3 2025 results on November 4, 2025. Consensus estimates project revenue of $328.86 million and EPS of -$0.19.
Analyst Sentiment
Available analyst signals point toward bullish positioning, with price targets ranging from $60 to $110 per share. While comprehensive consensus ratings are not yet available in the current data, technical signals have mentioned the potential for a push toward $100 based on chart patterns and momentum indicators. Investors should verify current analyst coverage through financial platforms before making investment decisions.
Is Tempus AI a Good Stock to Buy?
Evaluating whether TEM represents a compelling investment opportunity requires weighing multiple factors. The bull case centers on strong revenue growth, consistent quarterly beats, and positioning within the expanding AI healthcare market. The company’s ability to exceed revenue expectations and narrow quarterly losses demonstrates execution on its operational strategy.
Investment Considerations
The fundamental picture reveals a company still in growth mode, with negative EPS of -$1.18 and a negative P/E ratio reflecting ongoing losses. This is not uncommon for technology and healthcare growth companies investing heavily in expansion. Revenue of $693.40 million annually provides a substantial top-line foundation, though the path to profitability remains a key question for long-term investors.
TEM exhibits elevated volatility with beta readings between 2.74 and 3.04, meaning the stock tends to move more aggressively than the broader market in either direction. A 6.31% daily volatility figure and the 52-week range spanning $22.89 to $104.32 indicate significant price swings. These characteristics suit growth-oriented, risk-tolerant investors but may not align with those seeking stability or income.
The approximately 96.24 million share float provides reasonable liquidity for institutional participation. The $300 million acquisition funding for Ambry Genetics signals continued strategic expansion, though acquisitions carry integration risks and capital deployment considerations.
No specific 2030 forecasts are currently available in verified sources, and readers seeking longer-term predictions should consult financial advisors or subscription research services that provide such forward-looking analysis. Short-term technical targets suggest $80–$110 potential based on historical patterns, though past performance does not guarantee future results.
For those interested in comparing this stock with consumer electronics offerings in the technology space, readers may find our guide on the Galaxy S25 FE to Buy – Release Date, Price, Specs & Deals or the iPhone Pro Max 17 – Release Date, Specs and Price useful for understanding broader tech market dynamics.
Tempus AI Price Timeline
- June 25, 2024 – TEM reaches 52-week low of $22.89, marking the trough of recent trading range
- October 9, 2025 – Stock achieves 52-week high of $104.32, representing peak momentum
- Q2 2025 – Quarterly revenue of $314.63 million beats estimates; EPS loss narrows to -$0.22
- Recent – Tempus AI secures $300 million for Ambry Genetics acquisition
- November 4, 2025 – Scheduled Q3 2025 earnings release with projected revenue of $328.86 million
What We Know Versus What Remains Uncertain
Confirmed Information
- TEM trades on Nasdaq with prices ranging $49.53–$68.09 recently
- 52-week range spans $22.89 to $104.32
- Revenue growth and quarterly earnings beats are documented
- Beta of 2.74–3.04 confirms high volatility characteristics
- Market cap estimated at $9.76B–$15.91B depending on timing
- $300M acquisition funding announced for Ambry Genetics
- Next earnings scheduled November 4, 2025
Unconfirmed or Unclear
- Specific 2030 price predictions are not available in verified sources
- Full analyst consensus ratings remain incomplete
- Exact current price varies across platforms due to timing differences
- Integration timeline and costs for Ambry Genetics acquisition
- Precise path to profitability remains undefined
- Complete analyst coverage details require verification
Tempus AI in Market Context
Tempus AI operates at the convergence of two high-growth sectors: artificial intelligence and healthcare data analytics. The company leverages machine learning to process clinical and molecular data, enabling personalized medicine applications and research partnerships with healthcare providers, pharmaceutical companies, and research institutions.
The broader AI healthcare market has experienced substantial expansion as healthcare systems seek efficiency gains and personalized treatment protocols. Companies demonstrating ability to translate AI capabilities into actionable clinical insights have attracted premium valuations, though execution risk and competitive pressures remain persistent factors.
The high beta reading of approximately 3.04 means TEM typically amplifies broader market movements, making it more sensitive to shifts in investor sentiment toward growth and technology stocks. This characteristic can work both for and against investors depending on market direction.
Data Sources and Verification
This analysis draws on multiple verified financial data providers to present a comprehensive picture of Tempus AI’s current standing. Live trading data reflects snapshots from major platforms including Robinhood, TradingView, Kraken, StockTwits, and Google Finance.
Market data from multiple sources shows price inconsistencies likely due to timing variations. Readers should verify current pricing through their preferred financial platform before making trading decisions.
Financial metrics including P/E ratios, EPS figures, and revenue data derive from quarterly filings and consensus estimates compiled by financial data services. The acquisition funding announcement and earnings beat information reflect verified corporate disclosures.
For official corporate communications, investors can access Tempus AI’s investor relations page directly. Regulatory filings are available through SEC EDGAR, providing authoritative documentation of financial performance and strategic initiatives.
Summary
The Tempus AI share price reflects a company navigating significant growth opportunities in AI-powered healthcare while managing the challenges inherent to pre-profitability growth stages. TEM has demonstrated strong momentum over the past year with a 98.24% gain, yet faces ongoing volatility and persistent losses that warrant careful consideration. The upcoming earnings release on November 4, 2025, will provide important signals regarding the company’s progress toward sustainable profitability and the successful integration of the Ambry Genetics acquisition.
Frequently Asked Questions
What is Tempus AI’s current stock price?
Recent trading ranges from $49.53 to $68.09 depending on timing and data source, with the most recent snapshots around $54.50. Prices fluctuate throughout the trading day.
Has Tempus AI ever been above $100?
Yes. TEM reached its 52-week high of $104.32 on October 9, 2025, though it has subsequently traded significantly lower in more recent sessions.
When does Tempus AI report earnings next?
The next earnings release is scheduled for November 4, 2025, covering Q3 2025 financial results. Analysts estimate revenue of $328.86 million and EPS of -$0.19.
Is Tempus AI profitable?
Tempus AI is not currently profitable on a GAAP basis, with EPS of -$1.18 over the trailing twelve months. However, quarterly losses are narrowing, with recent Q2 results showing a 37.03% improvement in net income quarter-over-quarter.
What analyst price targets exist for TEM?
Available analyst signals suggest price targets ranging from $60 to $110, with some bullish technical analysis pointing toward the $100 level. Comprehensive consensus ratings require verification through financial platforms.
Does Tempus AI pay dividends?
No dividend yield has been reported for TEM. The company appears to be reinvesting capital into growth initiatives rather than distributing profits to shareholders.
What acquisition has Tempus AI recently announced?
Tempus AI secured $300 million in funding specifically allocated for the Ambry Genetics acquisition, expanding the company’s genomic testing capabilities and healthcare data assets.
How volatile is TEM stock?
With a beta of 2.74 to 3.04 and daily volatility of 6.31%, TEM is significantly more volatile than the broader market. The 52-week price range from $22.89 to $104.32 illustrates the extent of historical price swings.
Where can I find official Tempus AI financial filings?
Corporate financial information and official statements are available through Tempus AI’s investor relations website, while regulatory filings can be accessed via the SEC EDGAR database.
What is Tempus AI’s market capitalization?
Market cap estimates range from approximately $9.76 billion to $15.91 billion depending on the price data and share count used in the calculation, with discrepancies reflecting timing variations across data sources.
More related posts
Premium Economy British Airways – Worth the Extra Cost?
Marks and Spencer Newcastle – Hours Location Services Guide
What Is a URL – Definition, Components and Examples
Kelly Brooks – Biography, Age, Husband, and Yellowstone Truth
Cast of Hijack (TV Series) – Full Seasons 1 and 2 Cast List
Seema Jaswal – Husband, Children, Religion, Salary and Biography
Tyson Fury – Complete Guide to His Career, Record and Next Fight
Bicarbonate of Soda vs Baking Soda – Key Differences Explained
